Design Therapeutics, Inc. (DSGN) stock
DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.47−0.37 (-3.76%)
Close on Nov 18, 2026Market cap $592.65MP/E –Yield –
Design Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Design Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$55.14M. For fiscal 2025 it was -$54.55M. The highest annual figure on record is -$8.75M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$54.55M | – |
| FY2024 | Dec 31, 2024 | -$43.45M | – |
| FY2023 | Dec 31, 2023 | -$58.82M | – |
| FY2022 | Dec 31, 2022 | -$52.24M | – |
| FY2021 | Dec 31, 2021 | -$30.92M | – |
| FY2020 | Dec 31, 2020 | -$8.75M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.16M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.42M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.59M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.38M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.21M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.74M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.13M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.86M | – |
See a number that looks wrong?